Hemophilia A
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- The most common form of hemophilia characterized by spontaneous or prolonged hemorrhages due to factor VIII deficiency.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Hemophilia A
- Therapeutic area
- Hematology
- hemophilia A
- congenital factor VIII disorder
- factor VIII deficiency
- haemophilia a, X-linked recessive
- haemophilia type A
- haemophilia type a
- hemophilia A
- hemophilia a, X-linked recessive
- hemophilia type A
- hemophilia type a
- hereditary Factor VIII deficiency
- hereditary Factor VIII deficiency disease
- HEMA
- Haemophilia A
- autosomal haemophilia a
- classic haemophilia
- classic hemophilia
- classical haemophilia
- classical hemophilia
- factor 8 deficiency
- haemophilia A, congenital
- hem A
- hemophilia A, congenital
- All therapeutic areas
- Hematology
- Severity
- Severe
- Genetic
- Hereditary
- MONDO ID
- MONDO:0010602
- Parent condition
- MONDO:0000425
Related records
Broader conditions (13)
- Blood coagulation disease
- Coagulation protein disease
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hematologic disorder
- Hemophilia
- Hemorrhagic disease
- Hereditary disease
- Human disease
- Inherited blood coagulation disorder
- X-linked disease
Narrower conditions (5)
- Hemophilia A with vascular abnormality
- Mild hemophilia A
- Moderately severe hemophilia A
- Severe hemophilia A
- Symptomatic form of hemophilia A in female carriers
Trials (789)
- 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece
- 3D Ultrasound in Hemophilic Ankles
- A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health
- A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children
- A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
- A Feasibility Study to Collect Data in Patients With Haemophilia
- A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A
- A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
- A Gene Transfer Study for Hemophilia A
- A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
- A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
- A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A
- A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
- A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
- A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care
- A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip
Approved drugs (19)
- Antihemophilic factor, pegylated (MW 20000) human sequence recombinant
- Damoctocog alfa pegol
- Efanesoctocog alfa
- Efmoroctocog alfa
- Emicizumab
- Eptacog alfa (activated)
- Eptacog beta (activated)
- Human coagulation factor VIII
- Lonoctocog alfa
- Marstacimab
- Moroctocog alfa
- Octocog alfa
- Simoctocog alfa
- Susoctocog alfa
- Tranexamic acid
- Turoctocog alfa
- Turoctocog alfa pegol
- Valoctocogene roxaparvovec
- Von willebrand factor human
Drugs in development (18)
- Anti-inhibitor coagulant complex Phase 3
- Antithrombin III human Phase 3
- Ataluren Phase 2
- BAY-1093884 Phase 2
- Concizumab Phase 3
- Denecimig Phase 1
- Dirloctocogene samoparvovec Phase 1
- Eptacog alfa pegol (activated) Phase 1
- Fitusiran Phase 3
- Giroctocogene fitelparvovec Phase 3
- Marzeptacog alfa (activated) Phase 1
- Omfiloctocog alfa Phase 3
- Oprelvekin Phase 2
- Prednisone Phase 2
- Rituximab Phase 2
- Rondaptivon pegol Phase 1
- Thrombin Phase 2
- Vatreptacog alfa (activated) Phase 2
Other linked drugs (1)
- Desmopressin